WO2004056979A3 - Production de virus recombines pour la fabrication de vaccins - Google Patents

Production de virus recombines pour la fabrication de vaccins Download PDF

Info

Publication number
WO2004056979A3
WO2004056979A3 PCT/EP2003/051034 EP0351034W WO2004056979A3 WO 2004056979 A3 WO2004056979 A3 WO 2004056979A3 EP 0351034 W EP0351034 W EP 0351034W WO 2004056979 A3 WO2004056979 A3 WO 2004056979A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccines
cells
recombinant
production
manufacturing
Prior art date
Application number
PCT/EP2003/051034
Other languages
English (en)
Other versions
WO2004056979A2 (fr
Inventor
Menzo Jans Emco Havenga
Ronald Vogels
Sanne Melles
Original Assignee
Crucell Holland Bv
Menzo Jans Emco Havenga
Ronald Vogels
Sanne Melles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv, Menzo Jans Emco Havenga, Ronald Vogels, Sanne Melles filed Critical Crucell Holland Bv
Priority to CA002501975A priority Critical patent/CA2501975A1/fr
Priority to EP03799578A priority patent/EP1590450A2/fr
Priority to AU2003299244A priority patent/AU2003299244A1/en
Publication of WO2004056979A2 publication Critical patent/WO2004056979A2/fr
Priority to US11/146,332 priority patent/US20050221493A1/en
Publication of WO2004056979A3 publication Critical patent/WO2004056979A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • C12N2770/36162—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne la production de virus recombinés et/ou de protéines virales recombinées à partir de cellules pouvant se développer dans une suspension et dans un milieu de culture exempt de sérum sans qu'il faille utiliser des composantes dérivées d'animaux ou d'humains. L'invention concerne plus particulièrement la production d'alphavirus recombinés pouvant être utilisés dans des vaccins et en thérapie génique. L'invention concerne plus précisément la production de particules d'un virus de la Forêt de Semliki (SFV) transportant un gène hétérologue étudié (un antigène, par exemple) sur des cellules humaines non tumorales transformées par E1, de préférence dérivées de rétinoblastes primaires, telles que des cellules PER.C6™.
PCT/EP2003/051034 2002-12-04 2003-12-17 Production de virus recombines pour la fabrication de vaccins WO2004056979A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002501975A CA2501975A1 (fr) 2002-12-20 2003-12-17 Production de virus recombines pour la fabrication de vaccins
EP03799578A EP1590450A2 (fr) 2002-12-20 2003-12-17 Production de virus recombines pour la fabrication de vaccins
AU2003299244A AU2003299244A1 (en) 2002-12-20 2003-12-17 Recombinant virus production for the manufacturing of vaccines
US11/146,332 US20050221493A1 (en) 2002-12-04 2005-06-06 Recombinant virus production for the manufacturing of vaccines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02102861.8 2002-12-20
EP02102861 2002-12-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/146,332 Continuation US20050221493A1 (en) 2002-12-04 2005-06-06 Recombinant virus production for the manufacturing of vaccines

Publications (2)

Publication Number Publication Date
WO2004056979A2 WO2004056979A2 (fr) 2004-07-08
WO2004056979A3 true WO2004056979A3 (fr) 2007-10-11

Family

ID=32668896

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/051034 WO2004056979A2 (fr) 2002-12-04 2003-12-17 Production de virus recombines pour la fabrication de vaccins

Country Status (4)

Country Link
EP (1) EP1590450A2 (fr)
AU (1) AU2003299244A1 (fr)
CA (1) CA2501975A1 (fr)
WO (1) WO2004056979A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ567817A (en) 2005-11-01 2012-01-12 Novartis Vaccines & Diagnostic Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment
EP2531592A1 (fr) 2010-02-04 2012-12-12 Vivalis Procédé à alimentation discontinue utilisant un milieu de culture de cellules concentré pour la production efficace de produits biologiques dans des cellules eb66
CN111057685B (zh) * 2019-07-27 2022-03-18 中国人民解放军军事科学院军事医学研究院 一种复制型4型腺病毒载体重组马尔堡病毒病疫苗

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007571A1 (fr) * 1999-04-23 2001-02-01 Introgene B.V. Systemes et procedes de transfert d'acide nucleique
EP1103610A1 (fr) * 1999-11-26 2001-05-30 Introgene B.V. Production de vaccins de lignées de cellules mammifère immortalisées
WO2002077221A1 (fr) * 2001-03-27 2002-10-03 New York University Lignees cellulaires d'encapsidation pour la production continue de vecteurs d'alphavirus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007571A1 (fr) * 1999-04-23 2001-02-01 Introgene B.V. Systemes et procedes de transfert d'acide nucleique
EP1103610A1 (fr) * 1999-11-26 2001-05-30 Introgene B.V. Production de vaccins de lignées de cellules mammifère immortalisées
WO2002077221A1 (fr) * 2001-03-27 2002-10-03 New York University Lignees cellulaires d'encapsidation pour la production continue de vecteurs d'alphavirus

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FALLAUX F ET AL: "New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses", HUMAN GENE THERAPY, vol. 9, no. 9, 1 September 1998 (1998-09-01), pages 1909 - 1917, XP002111070, ISSN: 1043-0342 *
FROLOV I ET AL: "ALPHAVIRUS-BASED EXPRESSION VECTORS: STRATEGIES AND APPLICATIONS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 93, no. 21, 1996, pages 11371 - 11377, XP000910193, ISSN: 0027-8424 *
POWERS A M ET AL: "Evolutionary relationships and systematics of the Alphaviruses", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 75, no. 21, November 2001 (2001-11-01), pages 10118 - 10131, XP002238072, ISSN: 0022-538X *
SMERDOU C ET AL: "Two-helper RNA system for production of recombinant Semliki Forest virus particles", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 73, no. 2, February 1999 (1999-02-01), pages 1092 - 1098, XP002139369, ISSN: 0022-538X *

Also Published As

Publication number Publication date
CA2501975A1 (fr) 2004-07-08
EP1590450A2 (fr) 2005-11-02
AU2003299244A1 (en) 2004-07-14
WO2004056979A2 (fr) 2004-07-08

Similar Documents

Publication Publication Date Title
ATE472335T1 (de) Chimere alphavirus-replikon-partikel
PT1465987E (pt) Produção de vírus, isolados virais e vacinas
IL143441A0 (en) Non-naturally occuring antigen arrays and processes for the preparation thereof
PT1651666E (pt) Vacinas de citomegalovírus à base de alfavírus
WO2003072720A3 (fr) Systemes d'expression de virus recombinant parainfluenza et vaccins comprenant des antigenes heterologues derives de metapneumovirus
MX342639B (es) Virus de la influenza recombinantes de alta titulacion para vacunas y terapia genica.
MX2007007889A (es) Rescate del virus de influenza.
IL189766A0 (en) Methods for vaccine production and interferon deficient substrates
DE60233061D1 (de) Alphavirus replikon-vektorsysteme
WO2003039459A3 (fr) Procedes de preparation de vecteurs viraux et compositions associees
WO2004042001A3 (fr) Particules pseudovirales, procede de fabrication et compositions immunogeniques
WO2005027825A3 (fr) Systemes d'expression de virus parainfluenza recombinant et vaccins comportant des antigenes heterologues derives du metapneumovirus
AU5998400A (en) In vitro reconstitution of segmented negative-strand rna viruses
AU2001275191A1 (en) Method for the purification of alphavirus replicon particles
WO2003023032A3 (fr) Evolution dirigee a capacite elevee par mutagenese rationnelle
CY1107632T1 (el) Διαδικασια για την παρασκευη μιας θρομβινης στην οποια εχουν αδρανοποιηθει οι ιοι
WO2006136448A3 (fr) Sras attenue: utilisation comme vaccin
WO2003072725A3 (fr) Systemes et vaccins d'expression d'arn a brin negatif recombinant
IL168374A (en) Vaccines against west nile virus
WO2007046839A3 (fr) Nouveaux vaccins a base de virus vivant
WO2004056979A3 (fr) Production de virus recombines pour la fabrication de vaccins
WO2002027007A3 (fr) Production de vecteurs viraux
AU2003250680A1 (en) Recombinant vesicular stomatitis virus vaccines for viral hemorrhagic fevers
HUP0401585A2 (hu) Fertőző, marhában előforduló, vírusos hasmenés vírusklónja
MXPA02012593A (es) Particulas de tipo virus del virus de la diarrea viral bovina.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 539231

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003799578

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2501975

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003299244

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 11146332

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2003799578

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2003799578

Country of ref document: EP